Abstract
Background
We showed feasibility and efficacy of topotecan in third or a higher line of chemotherapy in heavily pretreated ovarian cancer (HPOC) patients.
Methods
Between January 2004 and June 2007, 25 cases of HPOC were treated with topotecan as 30-min infusion at the dose of 1.5 mg/m2 through 5 consecutive days every 21 days. We assessed toxicity profile using NCI CTC and the response was measured according to RECIST and CA-125 criteria described by Rustin.
Results
Heavily pretreated ovarian cancer received at least two cycles of topotecan (median 6, range 2–6) with prior chemotherapy lines (median 3, range 3–7). In 20 HPOC who met RECIST criteria results were as follows: PR, 6/20 (30%); NC, 7/20 (35%); PD, 7/20 (35%). Biochemical response was noted in 20 patients having ?15% (3/20) of 75% and 20% (4/20) of 50% decline of CA-125. Time to progression was median 6 months (95% CI: 4.06–6.18) and overall survival was median 9 months (95% CI: 8.69–16.27). In multivariate analysis, primary optimal debulking and response to primary chemotherapy (HR = 0.24, 95% CI: 0.08–0.69, P = 0.0084; HR = 0.38, 95% CI: 0.14–0.98, P = 0.0448, respectively) were independent prognostic factors when assessed in relation to salvage therapy with topotecan. We did not observe difference in side effects after topotecan treatment among patients in relation to the higher number of previously used chemotherapy line (3 vs. >3).
Conclusions
We state that topotecan is able to offer a control of ovarian cancer, despite previous treatment, but reliable management is needed to alleviate hematologic toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armstrong DK, Spriggs D, Levin J, Poulin R, Lane S (2005) Hematologic safety and tolerability of topotecan in recurrent ovarian cancer and small cell lung cancer: an integrated analysis. Oncologist 10:686–694. doi:10.1634/theoncologist.10-9-686
Bookman MA, Malmstrom H, Bolis G et al (1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345–3352
Common Terminology Criteria for Adverse Events, Version 3.0, revised 10 June 2003. National Cancer Institute, http://ctep.cancer.gov/forms/CTCAEv3.pdf
Creemers GJ, Lund B, Verweij J (1994) Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 20:73–96. doi:10.1016/0305-7372(94)90011-6
Creemers GJ, Bolis G, Gore M et al (1996) Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 14:3056–3061
Garcia AA (1999) Salvage therapy for ovarian cancer. Curr Oncol Rep 1:64–70. doi:10.1007/s11912-999-0012-8
Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ (2001) Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 19:3312–3322
Gordon AN, Tonda M, Sun S, Rackoff W (2004) Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95:1–8. doi:10.1016/j.ygyno.2004.07.011
Jemal A, Murray T, Samuels A, Ghafoor A, Word E, Thun M (2003) Cancer statistics, 2003. CA Cancer J Clin 53:5–26
Lynch T (1996) Topotecan today. J Clin Oncol 14:3053–3055
McGuire WP, Blessing JA, Bookman MA et al (2000) Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 18:1062–1067
Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Vermorken JB, van Lindert AC, Heintz AP, Aartsen E, van Lent M et al (1991) Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer. Eur J Cancer 27:1367–1372
Nielsen HA, Nielsen D, Engelholm SA (2000) Effect of topotecan on serum Ca-125 in patients with advanced epithelial ovarian cancer. Gynecol Oncol 77:383–388. doi:10.1006/gyno.2000.5760
Ozols RF (2002) Update on the management of ovarian cancer. Cancer J 8(Suppl 1):15–21
Piura B, Rabinovich A (2005) Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma. Int J Gynecol Cancer 15:612–617. doi:10.1111/j.1525-1438.2005.00116.x
Rocconi RP, Case AS, Straughn JM Jr, Estes JM, Partridge EE (2006) Role of chemotherapy for patients with recurrent platinum-resistant advanced epithelial ovarian cancer: a cost-effectiveness analysis. Cancer 107:536–543. doi:10.1002/cncr.22045
Rustin GJ, Nelstrop AE, Bentzch SM, Bond SJ, McClean P (2000) Selection of active drugs for ovarian cancer based on CA 125 and standard response rates in phase II trials. J Clin Oncol 18:1733–1739
Safra T, Menczer J, Bernstein R, Shpigel S, Inbar MJ, Grisaru D, Golan A, Levy T (2007) Efficacy and toxicity of weekly topotecan in recurrent epithelial ovarian and primary peritoneal cancer. Gynecol Oncol 105:205–210. doi:10.1016/j.ygyno.2006.11.017
Spannuth WA, Leath CA, Huh WK, Barnes MN, Davidson SA, Kilgore LC, Partridge EE, Austin JM, Alvarez RD (2007) A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy. Gynecol Oncol 104:591–595. doi:10.1016/j.ygyno.2006.09.008
Swisher EM, Mutch DG, Rader JS et al (1997) Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 66:480–486. doi:10.1006/gyno.1997.4787
Tangjitgamol S, See HT, Manusirivithaya S, Levenback CF, Gershenson DM, Kavanagh JJ (2004) Third-line chemotherapy in platinum- and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients. Int J Gynecol Cancer 14:804–814. doi:10.1111/j.1048-891X.2004.014512.x
ten Bokkel Huinink W, Gore M, Carmichael J et al (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183–2193
Therasse P, Arbuck SG, Eisenhauer E (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216. doi:10.1093/jnci/92.3.205
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bodnar, L., Wcislo, G., Nasilowska, A. et al. Salvage therapy with topotecan in heavily pretreated ovarian cancer patients. J Cancer Res Clin Oncol 135, 815–821 (2009). https://doi.org/10.1007/s00432-008-0517-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-008-0517-9